Bio-pharma company THC Global Group is licenced to produce medical cannabis from its Southport Manufacturing Facility.
According to THC Global, initial annual production could exceed 12,000kg of Active Pharmaceutical Ingredient (API) isolates, created under Good Manufacturing Practices (GMP) compliant methods.
“We expect to be supplying Australian patients with Australian produced medicinal cannabis by early 2020, as well as responding to the rapidly expanding global demand for pharma-grade GMP API isolates and formulated medicines,” said chief executive officer, Ken Charteris.
THC Global noted in a statement that there is a high demand globally for these isolates and a lack of suppliers able of meeting quality standards. As laws on the medical use of cannabis continue to be relaxed, THC Global expects cannabis usage to increase, while legislators seek to implement high regulatory standards for medical cannabis.
As well as the Southport site, THC Global operates another facility in south east Queensland, where the company has developed a proprietary cannabis strain in its lab and cultivation facility.
In future, the company will open a 150,000 square metre site in northern NSW which will focus on the cultivation of organic cannabis.
THC Global sees applications for medicinal cannabis in the treatment of cancer, HIV/AIDS, multiple sclerosis (MS) and chronic pain.
As the cannabis plants are grown, the plants are cultivated to produce stable levels of cannabinoids and not contain adulterants.
Cannabidiol (CBD) is absorbed by the body’s endocannabinoid system (ECS). The ECS works to regulate mood, sleep, appetite, reproduction, memory, immunity, and cell growth.
In Australia, the Commonwealth Department of Health, along with state and territory governments, have created an overview and clinical guidance for the use of CBD products for chemotherapy-induced nausea and vomiting, epilepsy, MS, chronic non-cancer pain, and palliative care.
THC Global is one of a number of medical manufacturers who have been granted licences this year, with Institute for Drug Technology Australia licenced to manufacture extracts and tinctures of cannabis and cannabis resin. In January, AusCann Group announced it will establish a research and development facility in Perth, Western Australia.